It is well known that food intake changes luminal conditions (e.g. pH, motility, microbiota,…) in the stomach and the small intestine, modifying drugs bioavailability. Food-drug interactions are one of the major challenges for oral-administered drugs, even more so if considering the growing use of food supplements and functional foods.
The endothelial cells that conform the BBB limit the passage of blood circulating endogenous substrates and larger molecules to the brain. This intrinsic protective role is also a major hurdle for reasearchers developing drugs for Central Nervous System (CNS) disorders.
Specialized manufacturer of in vitro kits indicated to evaluate pharmacological relevant efflux and uptake receptors for TDI assays.
PreadyPort BCRP is a in vitro system based on transfected MDCKII cells overexpressing the BCRP transporter.
MDCKII cells based in vitro system is a recommended model to evaluate blood-brain barrier permeability during CNS action novel compounds.